Carebastine Almirall Prodesfarma

Current Opinion in Investigational Drugs

Volumn 1, Issue 1, 2000, Pages 90-96

  Kingham, P ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAREBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LAS X 113;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; BIOSYNTHESIS; CLINICAL TRIAL; CUNNINGHAMELLA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HEART ARRHYTHMIA; HUMAN; NONHUMAN; REVIEW; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; XEROSTOMIA;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BUTYROPHENONES; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033760834     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine
2. A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients
3. 1 histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma
4. 1 antihistamine without alcohol interaction
5. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects
6. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine
7. Pharmacokinetics and pharmacodynamics of ebastine in children
8. 1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea-pigs, dogs and monkeys
9. 1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects
10. 14C]ebastine after repeated oral administration in rats
11. 14C]ebastine after a single administration in rats
12. 1-receptor antagonist
13. A method to determine the ability of drugs to diffuse through the blood-brain barrier
14. 1-receptor antagonist ebastine to its active metabolic carebastine
15. Terfenadine: A mixture of equipotent antihistamine enantiomers without a clear 'isomeric ballast'
16. Ebastine: A review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders
17. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects
18. 1-receptor anatagonist on human Kv1.5 channels
19. New directions in antihistamine research
20. Microbial oxidation of ebastine
21. Ebastine is without effect in a sensitive experimental model for detecting prolongation of the Qtc interval
22. 1-receptor antagonist on human Kv1.5 channels
23. 1 receptor antagonists on action potentials in gunea-pig isolated papillary muscles
24. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect
25. 1 receptor antagonist
26. Simultaneous compartmental model development for the pharmacokinetics of ebastine and carebastine
27. An ion spray LC-MS-MS method for the determination of ebastine and carebastine in human plasma
28. 1 receptor antagonist
29. Comparative pharmacokinetics of carebastine-ebastine in moderately renally impaired and healthy volunteers following a single 10 mg dose of ebastine
30. Single dose and steady-state pharmacokinetics of carebastine following administration of 10 mg ebastine tablets once daily in healthy elderly and young adults
31. Effect of food on the bioavailability of carebastine in healthy male volunteers
32. + currents by nonsedating H-1-antagonist ebastine in guinea-pig ventricular myocytes
33. Comparative pharmacokinetics of ebastine-carebastine in liver cirrhosis and healthy volunteers following administration of a 10 mg ebastine tablet
34. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine and in healthy subjects
35. Oral vs inhaled asthma therapy. Pros, cons and combinations
36. 1-receptor antagonist
37. Studies on the first-pass metabolism of ebastine in rats
38. 1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triproldine 10 mg on car driving performance
39. Drug therapy for ocular allergy
40. Carebastine nasal spray in the management of seasonal allergic rhinitis (SAR)
41. Carebastine eye drops in the management of seasonal allergic conjunctivtis (SAC)
42. Blood-brain barrier permeation: Molecular parameters governing passive diffusion
43. BioPartnering - Almirall Prodesfarma SA
44. Drug development pipeline: Carebastine
45. 1 receptor antagonists
46. The non-cardiac systemic side-effects of antihistamines: Ebastine
47. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats
48. American Academy of Allergy, Asthma and Immunology - 56th Annual Meeting (Part II) San Diego, CA, USA
49. Comparative study of different weighting methods in non-linear regression analysis: Implications in tha parametrization of carebastine after intravenous administration in healthy volunteers
50. The effect of carebastine eye drops in conjunctival provocation test (CPT) with allergens
51. Clinical pharmacokinetics of carebastine after intravenous and oral administration in healthy volunteers
52. Carebastine, administered topically, protects against allergic rhinorrhea (AR) without affecting either nasal epithelium (NE) or mucociliar transport velocity (MCT)
53. Dose response suppression of histamine induced wheal and flare by ebastine in allergic rhinitis patients
54. Suppression of the skin reaction to histamine by ebastine
55. Pharmacodynamic assessment of the efficacy of single and multiple doses of ebastine, cetirizine and loratidine against histamine induced cutaneous challenge in healthy volunteers
56. Assessment of the wheal size and skin blood flow of the erythema induced by histamine and its modification with cetirizine and ebastine: A crossover, double blind study
57. Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity
58. In vitro and in vivo anti-leukotriene effects of ebastine
59. Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma
60. The effect of food on the bioavailability of ebastine
61. N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450
62. Cardiac effects of ebastine and other antihistamines in humans
63. Comparison of once daily ebastine 20 mg, ebastine 10 mg, loratidine 10 mg, and placebo in the treatment of seasonal allergic rhinitis
64. A 12 week placebo controlled study on the efficacy and safety of ebastine, 10 mg and 20 mg once daily on the treatment of perennial allergic rhinitis
65. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis
66. The comparative efficacy and safety of ebastine 20 mg and 10 mg daily (OD) and loratidine 10 mg OD vs placebo during 4 week treatment of seasonal allergic rhinitis (SAR)
67. Risks of non-sedating antihistamines